EUCLID
Phase 3
- Conditions
- Peripheral Artery Disease
- Registration Number
- JPRN-jRCT2080222014
- Lead Sponsor
- AstraZeneca
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Symptomatic peripheral artery disease
Exclusion Criteria
- Patients needing dual anti-platlet drug treatment before start of study Planned revascularisation or amputation
- Patients with known bleeding disorders
- Patients with a history of intracranial bleed
- Patients considered to be at risk of bradycardic events unless already treated with a permanent pacemaker
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method